Drugs

PEER-REVIEWED FEATURE

Tremelimumab: Adis Evaluation

Key Points

- An anti-CTLA-4 antibody that is being developed by AstraZeneca, under license from Pfizer, for the treatment of malignant tumours
- Received its first approval on 21 October 2022 in the USA
- Approved for use in combination with durvalumab for the treatment of adult patients with uHCC, and in combination with durvalumab and platinum-based chemotherapy in mNSCLC

Summary

Tremelimumab (tremelimumab-actl; IMJUDO®), a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody, is being developed by AstraZeneca, under license from Pfizer, for the treatment of a range of malignant tumours

Tremelimumab was approved in the USA in October 2022 in combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).

In addition, tremelimumab in combination with durvalumab and platinum-based chemotherapy was approved in the USA in November 2022 for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) with no sensitizing epidermal growth factor receptor mutation or anaplastic lymphoma kinase genomic tumour aberrations.

In December 2022, tremelimumab in combination with durvalumab received a Positive Opinion from the EU Committee for Medicinal Products for Human Use for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. Tremelimumab in combination with durvalumab is under regulatory review for these indications in Japan and in other countries worldwide.

Keam S. K. Drugs. 2022. https://doi.org/10.1007/s40265-022-01827-8